Posted by Michael Wonder on 12 Feb 2024
FDA approves Takeda’s Eohilia (budesonide oral suspension), the first and only oral treatment in the US for eosinophilic oesophagitis
12 February 2024 - 12 weeks of treatment with Eohilia may address significant unmet needs of patients 11 years of age and older.
Takeda today announced that the US FDA has approved Eohilia (budesonide oral suspension), the first and only FDA approved oral therapy for people 11 years and older with eosinophilic oesophagitis.
